Protagonist Therapeutics Inc Market Cap ($5.09 Billion)
Market Cap & Net Worth: Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc market cap. Protagonist Therapeutics Inc (NASDAQ:PTGX) has a market capitalization of $5.09 Billion ($5.09 Billion) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3430 globally and #1228 in its home market, demonstrating a 0.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Protagonist Therapeutics Inc's stock price $139.37 by its total outstanding shares 62515666 (62.52 Million). Also see Protagonist Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Protagonist Therapeutics Inc Market Cap History (2016–2026)
Protagonist Therapeutics Inc market cap history from 2016 to 2026. Data shows growth from $1.37 Billion to $8.71 Billion (27.39% CAGR). Check PTGX stock price for real-time trading data and today's change.
Index Memberships
Protagonist Therapeutics Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.20% | #85 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.01% | #389 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.28% | #57 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.21% | #70 of 602 |
Weight: Protagonist Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Protagonist Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Protagonist Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PTGX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.55x
Protagonist Therapeutics Inc's market cap is 5.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.77x
Protagonist Therapeutics Inc's market cap is 8.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.30 Billion | $20.06 Million | -$36.96 Million | 64.81x | N/A |
| 2018 | $420.73 Million | $30.93 Million | -$38.92 Million | 13.60x | N/A |
| 2019 | $440.74 Million | $231.00K | -$77.19 Million | 1907.95x | N/A |
| 2020 | $1.26 Billion | $28.63 Million | -$66.15 Million | 44.02x | N/A |
| 2021 | $2.14 Billion | $27.36 Million | -$125.55 Million | 78.15x | N/A |
| 2022 | $682.05 Million | $26.58 Million | -$123.41 Million | 25.66x | N/A |
| 2023 | $1.43 Billion | $60.00 Million | -$78.95 Million | 23.89x | N/A |
| 2024 | $2.41 Billion | $434.43 Million | $275.19 Million | 5.55x | 8.77x |
Competitor Companies of PTGX by Market Capitalization
Companies near Protagonist Therapeutics Inc in the global market cap rankings as of November 3, 2026. Also see Protagonist Therapeutics Inc (PTGX) total assets for a full breakdown of the balance sheet.
Key companies related to Protagonist Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Protagonist Therapeutics Inc (2016–2026)
Market capitalization of Protagonist Therapeutics Inc from 2016 to today. Between 2016 and today, Protagonist Therapeutics Inc's market cap moved from $1.37 Billion to $ 8.71 Billion, with a yearly change of 27.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.71 Billion | +59.57% |
| 2025 | $5.46 Billion | +126.27% |
| 2024 | $2.41 Billion | +68.34% |
| 2023 | $1.43 Billion | +110.17% |
| 2022 | $682.05 Million | -68.10% |
| 2021 | $2.14 Billion | +69.64% |
| 2020 | $1.26 Billion | +185.96% |
| 2019 | $440.74 Million | +4.75% |
| 2018 | $420.73 Million | -67.64% |
| 2017 | $1.30 Billion | -5.41% |
| 2016 | $1.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Protagonist Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.09 Billion USD |
| MoneyControl | $5.09 Billion USD |
| MarketWatch | $5.09 Billion USD |
| marketcap.company | $5.09 Billion USD |
| Reuters | $5.09 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more